CORPORATE OVERVIEW
Progenitor Cell Therapy is a client-based cell therapy services company that supports the development of cellular therapies by providing cGMP-compliant cell manufacturing and consulting services that address regulatory, financial, technical, process, and quality systems strategies. PCT's cG(x)P nationwide network enables it to provide a full spectrum of support including preclinical development, clinical research, collection, processing, tissue storage, diagnostics/biologic product testing, manufacturing, distribution and transportation.

ESTABLISHED:
1997

FINANCIAL:
Privately held

WEBSITE:
http://www.progenitorcelltherapy.com

CONTACT:
Progenitor Cell Therapy, LLC
21 Main Street, Court Plaza South
East Wing, Suite 304
Hackensack, New Jersey 07601
Telephone: 201. 883.5300
Fax: 201. 883.1409
info@progenitorcelltherapy.com

LOCATIONS:
Headquarters - Corporate
21 Main Street, Court Plaza South
East Wing, Suite 304
Hackensack, New Jersey 07601
USA

East Coast Manufacturing
20 Prospect Avenue Suite #400
Hackensack, New Jersey 07601
USA

East Coast R&D
30 Prospect Avenue - 4th Floor
David Joseph Jurist Research Building
Hackensack, New Jersey 07601
USA

West Coast Manufacturing and R&D
291 N. Bernardo Avenue
Mountain View, California 94043
USA

MANAGEMENT TEAM:
Andrew L. Pecora, M.D., F.A.C.P.
Chairman, Chief Executive Officer and Chief Medical Officer, Member of Board of Managers

Robert A. Preti, Ph.D.
President and Chief Scientific Officer, Member of Board of Managers

George S. Goldberger
Chief Business and Financial Officer, Treasurer and Secretary

Stewart Craig, Ph.D
Chief Techical Officer & Vice President

Wai Shun Chan, Ph.D.
Scientific Director

Marie DeVito, M.Sc.
Senior Director of Quality Assurance and Quality Control


MARKET OVERVIEW
Progenitor Cell Therapy, LLC services are applicable throughout the entire field of cell therapy. The cell therapy market is experiencing rapid growth, and according to industry reports, the value of the 2005's international cell therapy market was estimated to be $26.6 billion. It has been projected that the market will reach $56.2 billion in 2010 and $96.3 billion in 2015*.

* Cell Therapy-Technologies, Markets, and Companies